Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma

Lower-grade gliomas exhibit a high prevalence of isocitrate dehydrogenase 1 (IDH1) mutations, but faithful models for studying these tumors are lacking. Here, we present a protocol to establish a genetically engineered mouse (GEM) model of grade 3 astrocytoma driven by the Idh1(R132H) oncogene. We d...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Diana D., Lee, Joyce H., Wang, Adam C., Khanal, Januka, Gao, Wenhua, Kaelin, William G., McBrayer, Samuel K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189469/
https://www.ncbi.nlm.nih.gov/pubmed/37149859
http://dx.doi.org/10.1016/j.xpro.2023.102281
Descripción
Sumario:Lower-grade gliomas exhibit a high prevalence of isocitrate dehydrogenase 1 (IDH1) mutations, but faithful models for studying these tumors are lacking. Here, we present a protocol to establish a genetically engineered mouse (GEM) model of grade 3 astrocytoma driven by the Idh1(R132H) oncogene. We describe steps for breeding compound transgenic mice and intracranially delivering adeno-associated virus particles, followed by post-surgical surveillance via magnetic resonance imaging. This protocol enables the generation and use of a GEM to study lower-grade IDH-mutant gliomas. For complete details on the use and execution of this protocol, please refer to Shi et al. (2022).(1)

Ejemplares similares